CLINICAL RESEARCH USING
NK IMMUNOMODULATORY FUNCTION IN 27 CANCER PATIENTS
BY MGN-3, A MODIFIED ARABINOXYLANE FROM RICE BRAN
M, Namatalla G.
Annual Meeting of the American Association for Cancer Research April
20-24,1996 Washington, DC
immunomodulatory function was examined in 27 cancer patients. MGN-3 is
an arabinoxylane from rice bran that has enzymatically modified by hyphomycetes
mycelia. The patients had different types of advanced malignancies:
patients had breast cancer,
multiple myelome (MM),
patients were under treatment with conventional therapy and were also given
3g of MGN-3 daily. NK activity was examined at 2 weeks, 3 months and 6
months. Activity of NK cells was examined by 5lCr-release assay using K562
tumor cells as targets, at effector:target ratios from 12:1- 100:1.
) Patients had low level of basal NK activity (10.8-40%),
treatment with MGN-3 caused a remarkable increase in NK activity at 2 weeks.
The percentages of induction were as follows: breast Ca 154-332%, prostatic
174-384%, leukemia 100-240%,MM 100-537%, and cervical CA 100-275%,
enhancement of NK activity continues to rise at 3 and 6 rnonths after treatment.
concluded that the high augmentory effect of MGN-3 makes it a promising
immunotherapeutic agent for treatment of cancer.